Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vanda Pharmaceuticals Inc. (VNDA)  
$4.92 0.06 (1.2%) as of 4:30 Wed 5/29


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 61,398,000
Market Cap: 302.08(M)
Last Volume: 687,618 Avg Vol: 703,347
52 Week Range: $3.38 - $6.66
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  803
Guru Rank Value     : 1
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 121,098 121,098 148,134 388,157
Total Sell Value $513,345 $513,345 $684,141 $2,735,436
Total People Sold 5 5 6 8
Total Sell Transactions 10 10 14 33
End Date 2024-02-29 2023-11-28 2023-05-30 2022-05-30

   
Records found: 554
  Page 14 of 23  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Irish Stephanie Rast Acting CFO/Treasurer   •       –      –    2010-02-18 4 OE $0.00 $0 D/D 20,000 22,449     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-14 4 S $10.73 $589,181 I/I (54,900) 2,715,852     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-13 4 S $10.54 $912,065 I/I (86,500) 2,770,752     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-12 4 S $10.88 $298,310 I/I (27,419) 2,857,252     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-11 4 S $11.00 $392,641 I/I (35,681) 2,884,671     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-05 4 S $11.48 $522,263 I/I (45,500) 2,920,352     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2010-01-04 4 S $11.65 $1,165,320 I/I (100,000) 2,965,852     -
   Polymeropoulos Mihael Hristos President and CEO   •       •      –    2009-12-15 5 GD $0.00 $0 D/D 20,000 405,000     -
   Ramsay David Russ Director   –       •      –    2009-12-15 4 S $11.03 $1,091,132 I/I (98,924) 200,000     -
   Karabelas Argeris N Director   –       •      –    2009-12-15 4 S $11.03 $1,091,132 I/I (98,924) 200,000     -
   Clark William D Sr. VP, Chief Business Officer   •       –      –    2009-12-14 4 S $11.05 $2,406,431 D/D (217,749) 152,801     -
   Clark William D Sr. VP, Chief Business Officer   •       –      –    2009-12-14 4 OE $0.33 $97,827 D/D 295,550 370,550     -
   Ramsay David Russ Director   –       •      –    2009-12-14 4 S $11.14 $1,448,200 I/I (130,000) 298,924     -
   Karabelas Argeris N Director   –       •      –    2009-12-14 4 S $11.14 $1,448,200 I/I (130,000) 298,924     -
   Ramsay David Russ Director   –       •      –    2009-12-09 4 S $11.57 $1,240,304 I/I (107,200) 428,924     -
   Karabelas Argeris N Director   –       •      –    2009-12-09 4 S $11.57 $1,240,304 I/I (107,200) 428,924     -
   Ramsay David Russ Director   –       •      –    2009-12-08 4 S $11.30 $298,049 I/I (26,376) 536,124     -
   Karabelas Argeris N Director   –       •      –    2009-12-08 4 S $11.30 $298,049 I/I (26,376) 536,124     -
   Karabelas Argeris N Director   –       •      –    2009-12-07 4 S $11.57 $1,157,000 I/I (100,000) 562,500     -
   Ramsay David Russ Director   –       •      –    2009-12-07 4 S $11.57 $1,157,000 I/I (100,000) 562,500     -
   Karabelas Argeris N Director   –       •      –    2009-12-04 4 S $11.70 $1,170,000 I/I (100,000) 662,500     -
   Ramsay David Russ Director   –       •      –    2009-12-04 4 S $11.70 $1,170,000 I/I (100,000) 662,500     -
   Feeney John Joseph Acting Chief Medical Officer   •       –      –    2009-11-06 4 S $10.33 $146,809 D/D (14,217) 0     -
   Feeney John Joseph Acting Chief Medical Officer   •       –      –    2009-11-06 4 OE $1.02 $91,098 D/D 14,217 14,217     -
   Tang Capital Partners Lp 10% Owner   –       –       •   2009-10-15 4 S $11.80 $683,782 I/I (57,928) 3,065,852     -
  554 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 23
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us